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Abstract
Background: Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) 
expansion in Huntingtin protein (Htt). PolyQ expansion in Httexp causes selective degeneration of striatal medium 
spiny neurons (MSN) in HD patients. A number of previous studies suggested that dopamine signaling plays an 
important role in HD pathogenesis. A specific inhibitor of vesicular monoamine transporter (VMAT2) tetrabenazine 
(TBZ) has been recently approved by Food and Drug Administration for treatment of HD patients in the USA. TBZ acts 
by reducing dopaminergic input to the striatum.
Results: In previous studies we demonstrated that long-term feeding with TBZ (combined with L-Dopa) alleviated the 
motor deficits and reduced the striatal neuronal loss in the yeast artificial chromosome transgenic mouse model of HD 
(YAC128 mice). To further investigate a potential beneficial effects of TBZ for HD treatment, we here repeated TBZ 
evaluation in YAC128 mice starting TBZ treatment at 2 months of age ("early" TBZ group) and at 6 months of age ("late" 
TBZ group). In agreement with our previous studies, we found that both "early" and "late" TBZ treatments alleviated 
motor deficits and reduced striatal cell loss in YAC128 mice. In addition, we have been able to recapitulate and quantify 
depression-like symptoms in TBZ-treated mice, reminiscent of common side effects observed in HD patients taking 
TBZ.
Conclusions: Our results further support therapeutic value of TBZ for treatment of HD but also highlight the need to 
develop more specific dopamine antagonists which are less prone to side-effects.
Background
Huntington's disease (HD) is an inherited progressive
neurodegenerative disorder characterized by chorea,
gradual but inexorable cognitive decline, and psychiatric
disturbances [1,2]. Selective and progressive neuronal
loss of the striatal medium spiny neurons (MSN) is the
major feature of neuropathological changes in HD [2].
The cause of HD is an expanded polyglutamine (polyQ)
in the amino-terminus of Huntingtin (Htt), a 350 kDa
ubiquitously expressed cytoplasmic protein of unknown
function [3]. The cellular mechanisms underlying the
cause of MSN neurodegeneration in HD are not very
clear, although most experimental evidences indicate that
polyQ expansion in Httexp leads to a "toxic gain of func-
tion" [4]. A number of toxic functions have been assigned
to Httexp, such as effects on gene transcription, formation
of toxic aggregates, direct induction of apoptosis, disrup-
tion of key neuronal functions such as proteosomal or
mitochondrial functions, ubiquitination pathways, axonal
transport, endocytosis, synaptic transmission and cal-
cium signaling [4-11].
In addition to glutamatergic stimulation from the cor-
tex, the striatum is the predominant target of dopaminer-
gic neurons that originate from the substantia nigra [12].
There is increasing evidence that the dopaminergic sys-
tem may contribute to HD neuropathology [12]. Signifi-
cant reduction of striatal D1 and D2 receptor density has
been reported in HD patients [13-18] and HD mouse
models [19-22]. High concentration of dopamine may
exert direct toxic effects on striatal neurons [23-28].
Hyperdopaminergic transmission has been shown to
accelerate the formation of Httexp aggregates and promote
motor dysfunction in 92Q knock-in HD mouse model
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[29]. Recent evidences from our group and from other
groups suggested that in HD dopaminergic and gluta-
matergic signaling pathways act synergistically to
enhance the sensitivity of striatal neurons to mutant hun-
tingtin toxicity via disturbed calcium homeostasis [30]
and disregulated Cdk5 signaling [31]. All these studies
pointed to an important role of dopaminergic pathway in
HD and suggested that dopamine signaling pathway con-
stitute a potential therapeutic target for HD treatment.
Tetrabenazine (TBZ) is a potent blocker of vesicular
monoamine transporter (VMAT2). In multiple clinical
trials TBZ has been shown to significantly reduce chorea
symptoms in HD patients when compared with placebo
group [32-35]. In our previous experiments with YAC128
mouse model of HD we demonstarted that long term
administration of TBZ (in combination with L-dopa) alle-
viated motor deficits and reduced striatal cell loss in these
mice [30]. In 2008 TBZ became the first drug officially
approved by the Food and Drug administration for treat-
ment of HD patients in the United States [35]. In clinical
setting most HD patients would receive TBZ at the symp-
tomatic stage after onset of the symptoms. To mimic clin-
ical situation more precisely, we now repeated evaluation
of TBZ in YAC128 HD mouse model and compared
results obtained in the "early" treatment group (starting
TBZ at 2 months, prior to onset of symptoms in YAC128
mice) and "late" treatment group (starting TBZ at 6
months, when motor symptoms start to develop in
YAC128 mice). Our results demonstrated significant ben-
eficial effects of TBZ in both "early" and "late" treatment
groups of YAC128 HD mice.
Results
TBZ improves motor coordination performance of YAC128 
HD mice
In the previous study we discovered that long-term oral
delivery of TBZ and L-Dopa combination (starting at 2
months of age) alleviated the motor deficits in aging
YAC128 mice [30]. In clinical setting most HD patients
would receive TBZ at the symptomatic stage after onset
of the symptoms. To compare the efficiency of "early" and
"late" treatments, we now repeated TBZ trial in vivo with
YAC128 mice model starting TBZ treatment early (2
months of age, "presymptomatic" mice) and late (6
months of age, "symptomatic" mice). The design of the
trial is shown on T able 1. In our studies the mice from
"early-TBZ" groups # 2 (YAC128) and # 5 (WT) were fed
with 0.125 mg of TBZ suspended in 50 μl of PBS with 2%
corn flour between 2 and 12 months of age (Table 1). The
control groups #1 (YAC 128) and # 4 (WT) mice were fed
with 2% cornflour in PBS between 2 and 12 months of age
(Table 1). The "late-TBZ" groups # 3 (YAC128) and # 6
(WT) were fed with 2% cornflour in PBS between 2 and 6
months of age and then fed with 0.125 mg of TBZ sus-
pended in 50 μl of PBS with 2% corn flour between 6 and
12 months of age (Table 1). The drugs were fed orally to
mice three times a week. At 12 months of age drug deliv-
ery to all 6 groups of mice was discontinued. The effec-
t i v e n e s s  o f  o r a l  d r u g  d e l i v e r y  w a s  d e t e r m i n e d  b y  2
months of "drug dosage" trial. We found that, 30 min after
feeding, TBZ concentration in blood plasma was 24 ± 7
ng/ml, that is 1.5-fold higher than our previous study
[30]. Most likely increase in blood TBZ levels is due to
difference in TBZ formulations used in the current and
previous studies.
The motor coordination of these 6 groups of mice was
assessed by "accelerated rotarod" and "beam-walk" assays
at 2, 6, 9, 11 and 13 (washout) months of age as described
in our previous studies [30,36]. Basal rotarod and beam-
walk performance for all groups was determined before
initiation of drug feeding when the mice were 2 months
of age. The length of time that the mice able to stay on
accelerated rotarod was used as a measure of rotarod per-
formance. When results were analyzed, we found that the
rotarod performance of WT and YAC128 mice was simi-
lar when these mice were 2 months of age (Fig. 1). Consis-
tent with the previous findings [30,37], control WT mice
(fed with PBS) performed significantly better in rotarod
assay (p < 0.05) than control YAC128 mice at 6, 9, 11 and
13 months of age (Fig 1). Feeding TBZ "early" to WT mice
had no apparent effects on their rotarod performance at 6
months, but caused significant (p < 0.05) reduction at 9
and 11 months when compared to control group. Feeding
TBZ "late" to WT mice had no apparent effects at 9
months, but caused significant (p < 0.05) reduction at 11
months when compared to control group (Fig 1). Consis-
tent with our previous findings [30], feeding TBZ "early"
to YAC128 mice significantly improved (p < 0.05) their
rotarod performance at 6, 9, 11 and 13 months when
compared to control group of YAC128 mice (Fig 1). Feed-
ing TBZ "late" to YAC128 mice also significantly
improved (p < 0.05) rotarod performance of these mice at
9, 11 and 13 months of age when compared to control
group of YAC128 mice. However, both YAC128 TBZ
feeding groups performed significantly worse (p < 0.05)
than any of the WT groups (Fig 1).
Two kinds of beams (11 mm round, and 5 mm square)
w e r e  u s e d  f o r  t e s t i n g  i n  b e a m - w a l k i n g  a s s a y .  T h e
"latency" and "number of foot slips" were measured for
each beam. When results were analyzed, we found that
consistent with our previous findings [30], the control
group of YAC128 mice (fed with PBS) exhibited a pro-
gressive impairment in beam-walking ability (longer
beam traverse latencies and increased number of foot
slips) with age and beam difficulty compared with control
group of WT mice. The significant differences (p < 0.05)
between beam performance of control YAC128 and con-
trol WT groups were observed at 9, 11 and 13 months ofWang et al. Molecular Neurodegeneration 2010, 5:18
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age on 11 mm round beam (Fig 2A, B); and at 6, 9, 11 and
13 months of age on 5 mm square beam (Fig 2C, D).
Feeding TBZ to WT mice had no significant effects on
beam performance of these mice (Fig 2A-D). However,
feeding TBZ to YAC128 mice improved their beam-walk-
ing performance, significantly (p < 0.05) shortening the
latencies and decreasing the foot slip numbers (Fig 2A-
D). Significant differences (p < 0.05) of latency between
YAC128 control group and early-TBZ-fed YAC128 group
were detected at 9, 11, 13 months of age on 11 mm round
beam (Fig 2A, B), and at 6, 9, 11 and 13 months of age on
5 mm square beam (Fig 2C, D). Late-TBZ feeding also
significantly (p < 0.05) improved the beam performance
of YAC128 mice at 9, 11 and 13 months of age on both 11
mm round beam (Fig 2A, B) and 5 mm square beam (Fig
2C, D). While conducting beam-walking assays, we
noticed that some aging mice exhibited periods of "crawl-
ing behavior" (defined as prolonged contact between the
thorax and abdomen of the mice and beam surface, with
the mice using forelimbs to drag themselves along the
beam). Three mice in YAC128 control group crawled on
11 mm round and 5 mm square beams at 11, 13 months
time point. In contrast, none of the mice in WT groups or
in YAC128 TBZ groups exhibited crawling behavior or
fell off the beams at any age tested.
At the conclusion of rotarod and beam-walking behav-
ioral experiments (13 months of age), we also assessed
gait abnormalities in all six groups of mice by footprint
pattern analysis (Fig 3A). The footprint patterns were
assessed quantitatively by five measurements: stride
length, hindbase width, frontbase width, front/hind foot-
print overlap and the ratio of hindbase and forebase as we
previously described [30,36]. We found that 13-month-
old control YAC128 mice exhibited shorter stride lengths
and increased front/hind paw overlap compared with
control WT mice (Fig 3B). Feeding TBZ to YAC128 mice
improved their stride lengths and overlap (Fig 3B). Our
analysis further revealed that, for the hindbase width,
Late-feeding TBZ to YAC mice slightly improved when
compared with control YAC group (Fig 3B). The front-
base width measurements are similar in all six groups of
mice. The ratio of hindbase and forebase showed similar
results with hindbase width analysis (Fig 3B).
The combined results from "rotarod" (Fig 1), "beam-
walk" (Fig 2), and "gait walk" (Fig 3) behavioral analysis
lead us to conclude that both "early" and "late" TBZ feed-
ing significantly alleviates motor deficits developed by
aging YAC128 mice.
Depression-related behaviors in TBZ-fed mice
In the process of behavioral testing we noticed that
behavioral performance of Early-TBZ feeding groups
(both WT and YAC) became impaired between 6, 9 and
11 months of age (Figs 1 and 2). We also noticed that the
mice in Early-TBZ feeding groups (both WT and
Table 1: Design of TBZ trial in YAC128 mice.
Group # Group name Number of mice Mouse genotype Single dose (50 μl)
(three times per week)
Drug dosage (mg/kg)
1 YAC-Ctrl 15 YAC128 50 μl PBS 50 μl PBS
2 YAC-TBZ (Early) 15 YAC128 0.125 mg of TBZ
(started at 2 months of age)
5 mg TBZ
3 YAC-TBZ (Late) 15 YAC128 0.125 mg of TBZ
(started at 6 months of age)
5 mg TBZ
4 WT-Ctrl 15 WT 50 μl PBS 50 μl PBS
5 WT-TBZ (Early) 15 WT 0.125 mg of TBZ
(started at 2 months of age)
5 mg TBZ
6 WT-TBZ (Late) 15 WT 0.125 mg of TBZ
(started at 6 months of age)
5 mg TBZ
Six groups of mice were used in our experiments. At 2 months of age, WT and YAC128 mice were divided into three groups each (15 mice in each 
group, 90 mice total, all females), and drug treatment was initiated. The drugs were fed orally to mice three times a week starting at 2 months of 
age for early groups and at 6 months of age for late groups. The group number, group name, number and genotype of mice in each group, and 
dose of single drug treatment (three times/week) are shown for each group. Also shown is the estimated drug dosage in mg/kg. Ctrl, Control; 
WT, wild type; YAC, YAC128.Wang et al. Molecular Neurodegeneration 2010, 5:18
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YAC128) appear to exhibit some symptoms of depres-
sion, such as hypoactivity and immobility in a tail suspen-
sion test. We started to observe these behavioral signs at
~7 months of age. We have not observed this phenome-
non in the previous study [30]. In the current study we
used 1.5-fold higher TBZ dosage compared to the previ-
ous study (based on TBZ blood concentration measure-
ments). Also, mice in the current study were fed with
TBZ three times per week compare with twice per week
in the previous study. In addition, in the previous study
we used TBZ + L-Dopa combination and now we used
TBZ alone. Most likely all these factors contributed to
"depression behavior" observed in the current study and
not in the previous study. This "depression phenomenon"
is of great interest since many HD patients taking TBZ
become severely depressed [32,38]. Thus, we performed
formal evaluation of these mice at 11 months of age using
Forced-Swim Test (FST) depression behavior paradigm.
We found that at 11 months of age YAC128 control group
recorded significantly greater FST immobility time than
WT control group (Fig 4). These results are consistent
with previous description of "depression symptoms" in
YAC128 mice using FST and additional behavioral para-
digms [39]. We further found that feeding TBZ to WT
mice significantly increased time of immobility in FST
test (Fig 4). Early TBZ feeding to YAC128 mice resulted
in increased time of immobility when compared to con-
trol YAC128 mice (Fig 4). Late TBZ feeding to YAC128
mice also increased time of immobity, but had less effect
in FST assay than early TBZ feeding (Fig 4).
Figure 1 Rotarod performance of WT and YAC128 mice. An average latency to fall from the accelerating rotarod is shown for the WT control (Ctrl) 
mice (open blue circles), the YAC128 (YAC) control mice (filled blue circles), the WT mice fed with Early-TBZ (open red squares), the YAC128 mice fed 
with Early-TBZ (filled red squares), the WT mice fed with Late-TBZ (open black triangles), and the YAC128 mice fed with Late-TBZ (filled black triangles). 
For each group of mice, the results are shown as mean ± SEM at 2, 6, 9, 11 and 13 month (washout) time points. At 6, 9, 11 and 13 months of age, 
control WT mice performed significantly better (p < 0.05) than control YAC128 mice. Early-TBZ feeding to WT mice had no apparent effects on their 
rotarod performance at 6 months, but caused significant (p < 0.05) reduction at 9 and 11 months when compared to control WT group. Similar to the 
Early-TBZ group, Late-TBZ feeding to WT mice had no apparent effects at 9 months, but caused significant (p < 0.05) reduction at 11 months compared 
to control WT group. Early-TBZ feeding to YAC mice significantly improved (p < 0.05) their rotarod performance at 6, 9, 11 and 13 months when com-
pared to control YAC128 mice. Late-TBZ feeding (6 months of age) to YAC mice significantly improved (p < 0.05) the rotarod performance at 9, 11 and 
13 months compared to control YAC128 mice. However, both YAC-TBZ feeding groups performed significantly worse (p < 0.05) than any of WT 
groups.Wang et al. Molecular Neurodegeneration 2010, 5:18
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TBZ protects against striatal cell loss in YAC128 HD mice
To evaluate potential neuroprotective effects of TBZ, at
the conclusion of behavioral trail (13 months time point)
the brains from all 6 groups of experimental mice were
removed from skull and weighted after transcardial per-
fusion. We found that the brains of control YAC128 mice
weighted significantly less (p < 0.05) than the brains of
control WT mice group (Fig 5A). Feeding TBZ to WT
mice had no significant effect on brain weight of these
mice (Fig 5A), whereas feeding TBZ to YAC128 mice
resulted in significant increase (p < 0.05) in brain weight
of these mice compared with control YAC128 (Fig 5A).
To obtain quantitative information about neuronal loss
in these mice, the neuropathological assessments were
performed by unbiased stereology as we previously
described [30,36]. The brains were fixed, frozen, and
sliced with the microtome, and coronal sections corre-
sponding to striatal region were stained with monoclonal
antibodies against NeuN protein. Representative NeuN
staining of striatal sections from each group of 13-
month-old WT and YAC128 mice are shown on Fig 5B.
The number of NeuN-positive neurons in the striatum
was counted blindly with respect to the nature of the
slices (genotype and drug treatment). By stereological
analysis, we determined that control YAC128 mice
showed significant striatal neuronal loss (p < 0.05) com-
pared with control WT mice (Fig 5C). We further found
that feeding of TBZ to WT mice did not cause significant
changes in striatal neuronal counts in these mice (Fig 5C).
However, TBZ feeding significantly increased striatal
neuronal counts (p < 0.05) in YAC128 mice (Fig 5C), indi-
cating that TBZ protects YAC128 MSNs from cell death.
Brain weight and MSN cell numbers were not signifi-
cantly different between Early-TBZ and Late-TBZ groups
Figure 2 Balance beam balance performance of WT and YAC128 mice. The average time to cross the beam (A, C) and the average number of 
foot slips on the beam (B, D) are shown for beam-walking performed with 11 mm round beam (A, B), and 5 mm square beam (C, D). The data for WT 
control (Ctrl) mice (open blue circles), YAC128 (YAC) control mice (filled blue circles), WT mice fed with Early-TBZ (open red squares), YAC128 mice fed 
with Early-TBZ (filled red squares), WT mice fed with Late-TBZ (open black triangles), and YAC128 mice fed with Late-TBZ (filled black triangles) are 
shown as mean ± SEM at 2, 6, 8, 11 and 13 month time points. Control YAC128 mice exhibited a progressive impairment in beam-walking ability with 
age and beam difficulty compared with control WT mice. The significant differences (p < 0.05) between control YAC128 and control WT groups were 
observed at 9, 11 and 13 months of age on 11 mm beam; and at 6, 9, 11 and 13 months of age on 5 mm beam. Feeding TBZ to WT mice had no 
significant effects on beam performance compared to control WT group. Early-TBZ feeding significantly (p < 0.05) improved the beam performance 
of YAC128 mice at 9, 11 and 13 months of age on 11 mm beam, and at 6, 9,11 and 13 months of age on 5 mm beam. Late-TBZ feeding also significantly 
(p < 0.05) improved the beam performance of YAC128 mice at 9, 11 and 13 months of age on both 11 mm and 5 mm beam.Wang et al. Molecular Neurodegeneration 2010, 5:18
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of YAC128 mice, with both groups showing similar
degree of improvement when compared to control
YAC128 group (Fig 5A, C). The results of our neuro-
pathological analysis indicated that "early" and "late" feed-
ing with TBZ significantly protected striatal neurons
from cell death in aging YAC128 mice.
Discussion
Striatum is the predominant target of midbrain dopamin-
ergic neurons [12], and a number of experimental evi-
dence point to a connection between dopamine signaling
and MSN neurodegeneration in HD [26]. Striatal MSN
neurons expressing dopamine receptors in the striatum
predominantly degenerate in HD patients, with cerebral
cortex neurons being affected to a much lower extent,
and striatal interneurons being spared [40,41]. Biochemi-
cal analysis revealed progressive loss of striatal D1 and D2
receptors in post mortem HD brains [42-46]. Imaging
studies also reported reduction of striatal D1 and D2
receptors in HD patients [13,14] and in asymptomatic
HD mutation carriers [15-19,47,48]. Consistent with
analysis of human HD cases, drastic reduction of striatal
D1 and D2 receptor density [19,20] and deficiencies in D1
receptor-mediated signaling [21] were observed in R6/2
HD mouse model prior to onset of degeneration. In cellu-
lar models dopamine potentiates mutant huntingtin-
mediated neurotoxicity by acting via D1-class [30,31] and
D2-class [25] dopamine receptors. The HD-like motor
dysfunction and selective MSN degeneration have been
observed in the dopamine transporter knockout mice
[24]. The hyperdopaminergic transmission accelerated
formation of Httexp  a g g r e g a t e s  i n  9 2 Q  k n o c k - i n  H D
mouse model [29]. In our previous study we reported that
feeding L-Dopa to YAC128 mice accelerated progression
of the motor phenotype and increased neuronal loss in
these mice [30]. Most of these findings are consistent
with an idea that dopamine exerts toxic effects on striatal
neurons in the context of HD mutation, which leads in
c o m p e n s a t o r y  l o s s  o f  D 1  a n d  D 2  r e c e p t o r s  i n  s t r i a t a l
region of HD brains.
Figure 3 Gait analysis of WT and YAC128 mice. A, The footprint patterns of 13-month-old YAC128 (YAC) and WT mice. The footprints for control, 
Early-TBZ, and Late-TBZ groups are shown for both WT and YAC128 mice. B, The footprint patterns were assessed quantitatively by five measurements: 
stride length, hindbase width, frontbase width, front/hind footprint overlap and the ratio of Hindbase and Forebase. 13-month-old control YAC128 
mice exhibited shorter stride lengths and increased front/hind paw overlap compared with control WT mice. Feeding TBZ to YAC mice improved their 
stride lengths and overlap. For the hindbase width, Late-feeding TBZ to YAC mice improved a little bit compared with control group. The frontbase 
width measurements are similar for all six groups of mice. The ratio of hindbase and forebase showed similar results with hindbase width analysis. Data 
for each measure are presented as mean ± SEM. * p < 0.05, significantly different from control YAC128 group.Wang et al. Molecular Neurodegeneration 2010, 5:18
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Striatal MSN loss is the hallmark of HD. Increasing evi-
dence suggested a permissive role of dopaminergic inner-
vation of the striatum in the excitotoxicity in HD.
Elevated glutamate-induced Ca2+ signals had been found
to play an important role in HD [9], and dopamine could
significantly potentiate glutamate-induced Ca2+  signals
and MSN death in HD model [30], suggesting that gluta-
mate and dopamine signaling pathways act synergistically
to induce elevated Ca2+ signals and to cause apoptosis of
HD MSNs [30]. D1 class DARs are coupled to Ca2+ signal-
ling via Gs/olf- cAMP-PKA, PKA activation modulates
the glutamate-related Ca2+ signaling pathway by facilitat-
ing the activity of NMDAR [49,50], AMPAR [51], and
InsP3R1 [52,53]. D2 class DARs directly coupled to Ca2+
signalling in MSNs via PLC activation. Therefore both D1
and D2 DARs might be involved in the potentiation
effects of dopamine on elevated Ca2+ signalling and cell
death in HD MSNs, and blockade of both D1 and D2
DARs would be necessary to exert significantly clinical
beneficial effects for dopamine antagonist treatment in
HD.
Ca2+ signalling is an important downstream in dop-
amine signalling cascades. In HD MSN, mutant Httexp
potentiates the activity of NR2B NMDAR [8,54-57] and
InsP3R1 [58], which in turn causes abnormal function and
cell death of HD MSN due to the disturbed Ca2+ signals.
Thus over activation of Ca2+ signaling by mutant Httexp
may lead to the compensatory loss of D1 and D2 recep-
tors in striatal region of HD brains. Indeed, a significant
reduction of striatal D1 and D2 receptors was found in
PET imaging studies [13,14] in HD patients and in HD
mouse models [19-21]. The idea of the compensatory loss
of D1 and D2 receptors are further supported by our ren-
c e n t  b e h a v i o r a l  e v a l u a t i o n  o f  d o p a m i n e  t o n e  i n  a g i n g
YAC128 HD mice (Wu at al, in preparation). Decreased
denisty of striatal monoaminergic terminals was found in
HD patients using DTBZ ((+)-alpha- [11C]dihydrotetra-
benazine) PET imaging technique [59], suggesting the
Figure 4 Forced-swim test (FST) evaluation of WT and YAC128 mice. 11-month-old mice were individually placed into a beaker of water (23-25°C) 
for a total of 300 secs and videotaped. Total immobility time of each mouse after the first 120 secs was manually scored by an experienced experi-
menter who was blinded to the genotype and drug treatment of the mice. YAC control group recorded significantly greater FST immobility time than 
WT control group (p < 0.05). Feeding TBZ to WT mice increased immobile than WT control mice (p < 0.05). Early-feeding TBZ to YAC mice exhibited 
more immobile compared with control YAC mice (p < 0.05). Late-feeding TBZ to YAC mice had no significant effect on depression-related behaviors 
compared with control YAC mice. ns, not significant.Wang et al. Molecular Neurodegeneration 2010, 5:18
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Figure 5 Neuropathological analysis of WT and YAC128 mice. A, Average brain weight of 13-month-old WT and YAC128 (YAC) mice. The brain 
weight of control YAC128 is significantly reduced compared with control WT group (p < 0.05). The brain weight of YAC128 mice fed with TBZ is sig-
nificantly increased compared with brain weight of control (Ctrl) YAC128 mice (*** p < 0.05). B, Representative NeuN staining of striatal sections from 
13-month-old WT and YAC128 mice. C, Average striatal neuronal counts of 13-month-old WT and YAC128 mice. Control YAC128 mice showed signif-
icant striatal neuronal loss (p < 0.05) compared with control WT mice. YAC128 mice fed with TBZ display significantly increased striatal neuronal counts 
compared with control YAC128 mice (*** p < 0.05) but significantly reduced neuronal counts compared with WT mice (*** p < 0.05). A, C, For each 
group of mice, the results are shown as mean ± SEM. Ctrl, Control.Wang et al. Molecular Neurodegeneration 2010, 5:18
http://www.molecularneurodegeneration.com/content/5/1/18
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deficits of presynaptic dopamine innervation in HD.
However, unlike the significant presynaptic nigrostriatal
dopaminergic denervation in Parkinson's disease, Hun-
tington's disease is characterized by more prominent stri-
atal dopamine receptor loss, whereas nigrostriatal
denervation is present to a lesser degree [60]. We explain
the decrease of dopaminergic inputs in HD as a compen-
satory effect of dopamine receptor loss in late stage of
HD.
Tetrabenazine (TBZ) is a potent blocker of vesicular
monoamine transporter (VMAT2). TBZ causes depletion
of dopamine content in the presynaptic vesicles and
reduction in the dopaminergic tone. In previous clinical
trials TBZ has been shown to significantly reduce chorea
symptoms in HD patients when compared with placebo
group [32-35]. In our previous experiments with YAC128
mouse model we demonstarted that long term adminis-
tration of TBZ (combined with L-Dopa) alleviated motor
deficits and reduced striatal cell loss in these mice [30].
These results indicated that TBZ and possibly other dop-
amine signaling antagonists may have a therapeutic
potential for treatment of HD beyond previously estab-
lished "symptomatic" benefit. In 2008 TBZ became the
first drug officially approved by the Food and Drug
administration for treatment of HD patients in the
United States [35], greatly enhancing the need to care-
fully characterize actions of this drug in the context of
HD models. We now repeated evaluation of TBZ in
YAC128 model of HD and compared "early" (2 months)
and "late" (6 months) treatment groups. We found that
both "early" and "late" TBZ treatments alleviated the
motor deficits (Figs 1, 2 and 3) and reduced striatal cell
loss (Fig 5) in YAC128 mice, suggesting that treatment of
both presymptomatic and early symptomatic HD patients
with TBZ may have neuroprotective effects and delay
progression of the disease. We should mentioned here
that, TBZ is not a specific dopamine depleting agent,
other neurotransmitter innervations such as serotoniner-
gic and some noradrenergic may also play a role in this
neuroprotective effects of TBZ.
By blocking VMAT2 TBZ depletes biogenic amines,
including dopamine as well as serotonin and norepineph-
rine. Reduced levels of serotonin can cause depression.
Indeed, it has been reported that many HD patients tak-
ing TBZ became severely depressed [32,38]. Interestingly,
we noticed that TBZ treatment groups of WT and
YAC128 mice exhibited some symptoms of depression,
such as hypoactivity and immobility in a tail suspension
test. We performed a formal depression behavior analysis
at 11 months of age for all 6 groups of mice by using
f o r c e d - s w i m  t e s t  ( F S T ) .  I n  t h i s  a n a l y s i s  w e  d i s c o v e r e d
that both "early" and "late" TBZ treatment groups of WT
and YAC128 mice appear to be depressed when com-
pared to control groups (Fig 4). Thus, we concluded that
TBZ is a useful therapeutic for treatment of HD, however
prolonged treatment with TBZ induces depression. Addi-
tional dopamine antagonists which do not interfer with
serotonin signaling system should be evaluated as poten-
tial HD therapeutics. The paradigms described in the
present study can be used for evaluation of beneficial
effects of these compounds for HD treatment as well as
their ability to cause depression-like behaviors. A novel
compound huntexil (pridopidine; ACR16) is a modulator
of D2 receptor activity [61,62] which has been recently
developed by NeuroSearch for treatment of movement
and psychiatric disorders. In recently completed phase III
HD clinical trial (MermaiHD study), Huntexil demon-
started significant clinical benefit http://www.neuro-
search.com/
Default.aspx?ID=16&M=News&PID=12&NewsID=1588
6. Importantly, further analyisis of results of phase III trial
suggested that Huntexil exerted not only symptomatic
benefit but was also able to slow the underlying disease
progression http://www.neurosearch.com/
Default.aspx?ID=16&M=News&PID=12&NewsID=1589
4. These clinical findings with Huntexil are consistent
with disease-modifying effects of TBZ that we observed
in the present and previous studies with YAC128 HD
mouse model (F ig 5 and [30]). I t will be of interest to
compare huntexil with TBZ and with other clinically rele-
vant D1 and D2 receptor antagonists in YAC128 mouse
model by following procedures described in the present
report. Obtained results will provide opportunity to sys-
tematically compare symptomatic and disease modifying
effects of these dopamine antagonists in HD, as well as
evaluate potential side effects such as induction of
depression.
Conclusions
Our present study demonstrated that TBZ, a dopamine
signaling antagonist have therapeutic potential for treat-
ment of HD beyond previously established "symptom-
atic" benefit. We found that both "early" and "late" TBZ
treatments alleviated the motor deficits and reduced stri-
atal cell loss in YAC128 mice, suggesting that treatment
of both presymptomatic and early symptomatic HD
patients with TBZ may have neuroprotective effects and
delay progression of the disease. Moreover, we have been
able to recapitulate and quantify depression-like symp-
toms in TBZ-treated mice, reminiscent of common side
effects observed in HD patients taking TBZ, highlighting
the need to develop and evaluate more specific dopamine
antagonists for HD treatment.
Methods
Drug delivery in mice
All animal studies were approved by the University of
T e x a s  S o u t h w e s t e r n  M e d i c a l  C e n t e r  A n i m a l  C a r e  a n dWang et al. Molecular Neurodegeneration 2010, 5:18
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Use Committee. YAC128 mice (FVBN/NJ background
strain) [37] were obtained from Jackson Labs (stock num-
ber 004938). Age-matched female wild type and YAC128
hemizygotous littermate mice were used in all our experi-
ments. Tetrabenazine (TBZ) was obtained from Tocris,
mixed with 2% cornflour using ceramic grinder and
resuspended in PBS. TBZ was delivered to mice by oral
feeding approach that we used in our previous studies
with YAC128 mice [30]. The drugs were fed orally to mice
three times a week starting at 2 months of age. The mice
were fed with 0.125 mg of TBZ suspended in 50 μl of PBS
with 2% corn flour. To determine the efficacy of this drug
delivery procedure, 7 wild-type mice of 2 months of age
were fed orally with 0.125 mg of TBZ formulation and the
blood samples were collected 30 minutes after drug feed-
ing. The samples were diluted 1:1 in water for hemolyza-
tion, flash frozen and shipped to Melior Discovery
(Exton, PA) for quantitative analysis. The TBZ levels were
analyzed using HPLC and compared with a standard TBZ
sample. Data are expressed as average of the values from
five samples ± SEM (see Results).
Motor coordination assessments in mice
The motor coordination experiments were performed as
previously described [30,36] with minor modifications.
The "beam-walking" assay was performed using a home-
built experimental setup. The 17 mm round beam, 11
mm round beam, and 5 mm square beam were used for
training. At each time point (2, 6, 9, 11 and 13 months of
age), the mice were trained to traverse the beam to the
enclosed box. The mice were trained on 17 mm round
beam for the 1st day, 11 mm round beam for the 2nd day,
and 5 mm square beams for the 3rd day (two trials per
day). Once the stable baseline of performance was
obtained, the mice were tested in two consecutive trials
on 11 mm round beam and then on 5 mm square beam,
in each case progressing from the widest to the narrowest
beam. The latency to traverse the middle section (80 cm
in length) of each beam and the number of times the hind
feet slipped off each beam were recorded for each trial.
For each measurement, the mean scores of the two trials
for each beam were used in the analysis.
The rotarod assessments were performed using Econo-
mex rotarod apparatus (Columbus Instruments, Colum-
bus, OH) as previously described [30]. At each time
point, the mice were trained on the accelerating rotarod
(accelerated from 0 to 40 rpm over 200 s) with 2 trials per
day for 3 consecutive days, by which time a steady base-
line level of performance was attained. The testing was
executed over 1 day with 1.5 h of rest between tests. The
mean latency to fall off the rotarod recorded in the two
trials is used in analysis.
For the footprint test, the forepaws and hindpaws of the
mice were coated with red and green nontoxic paints,
respectively. The mice were trained to walk along a 50-
cm-long, 10-cm-wide, paper-covered runway (with 10-
cm-high walls) into an enclosed box. All the mice were
given two runs per day for 3 consecutive days. A fresh
sheet of white paper was placed on the floor of the run-
way for each run. The footprint patterns were assessed
quantitatively by five measurements: stride length, hind-
base width, frontbase width, front/hind footprint overlap
and the ratio of hindbase and forebase as we previously
described [30].
Forced swim test
Immobility in the forced swim test (FST) is a commonly
used for measurement of depression in rodents [63-65].
Mice were individually placed into an individual glass
beaker (54 cm in height and 24 cm in diameter) filled
with room temperature water (23-25°C) to 40 cm depth.
All test sessions were recorded for a total of 300 seconds
by a video camera from the side of the cylinder. Total
immobility time of each mouse after the first 120 seconds
was manually scored by an experienced experimenter
who was blinded to the genotype and drug treatment of
the mice. Immobility was defined as the state in which
mice were judged to be making only the movements nec-
essary to keep their head above the surface.
Neuropathological assessments in mice
The neuropathological assessments were performed as
previously described [30]. At conclusion of behavioral
testing (13 months time point), the mice were terminally
anesthetized and perfused transcardially with 10 ml of
0.9% saline followed by 100 ml of fixative (4% paraformal-
dehyde in 0.1 M PBS, pH 7.4). All brains were removed
from the skull, weighed, and transferred to postfixative
overnight at 4°C in 4% paraformaldehyde and equili-
brated in 20-30% (w/v) sucrose in PBS. The brains were
processed and cut into 30-μm-thick coronal sections as
described above. The coronal sections spaced 360 μm
apart throughout the striatum (in the range from +1.70
mm to -2.30 mm relative to bregma) were stained with
NeuN monoclonal antibody (1:1000 dilution; Millipore,
Billerica, MA) and biotinylated anti-mouse secondary
antibodies (1:200 dilution; Vector Laboratories, Burling-
ton, Ontario, Canada) (M.O.M kit). Signal was amplified
with an ABC Elite kit (Vector Laboratories) and detected
with diaminobenzidine (Vector Laboratories). All quanti-
tative stereological analyses were performed blindly with
respect to the nature of slices (genotype and drug feed-
ing) using Stereoinvestigator setup and software (Micro-
BrightField, Williston, VT). The grid size was set to 450 ×
450 μm, and the counting frame was 50 × 50 μm. The
average slice thickness after histological processing was
determined to be 25 μm.Wang et al. Molecular Neurodegeneration 2010, 5:18
http://www.molecularneurodegeneration.com/content/5/1/18
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Statistical data analysis
The data were analyzed using SAS 9.13. The rotarod per-
formance and beam-working performance were analyzed
using 3 way ANOVA accounting for gene type (YAC128
vs wild type), drug treatment (PBS vs Early or Late-TBZ
feeding) and animals age for all factor analysis, 2 way
ANOVA for comparing treatment effects of Early or
Late-TBZ feeding vs PBS control, or Early or Late-TBZ
feeding in YAC128 and WT respectively, and 1 way
ANOVA for age effects in animals treated with PBS alone.
Tukey test or Student t test were also used where applica-
ble.
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